Regulators Closer to Harmonizing QbD Review Approaches Under Pilot
This article was originally published in The Gold Sheet
Executive Summary
Regulators in the U.S. and Europe are a little closer to harmonizing their reviews of new drug applications containing QbD elements under a joint review program. Areas of agreement include what is meant by QTPP and criticality, while areas of disagreement include NIR methods and design space development.
You may also be interested in...
In Brief
It’s time to comment on ICH Q11
In Brief
FDA mulls third-party inspections
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”